Predictive value of host-specific donor helper T-cell precursor frequency for acute graft-versus-host disease and relapse in HLA-identical siblings receiving allogeneic bone marrow transplantation for hematological malignancies

Transplantation

Volumn 64, Issue 8, 1997, Pages 1147-1152

  Lachance, Silvy ^a   Le Gouvello, Sabine ^a   Roudot, Françoise ^a   Kuentz, Mathieu ^a   Bernaudin, Françoise ^a   Beaujean, Françoise ^a   Bierling, Philippe ^a   Cordonnier, Catherine ^a   Farcet, Jean Pierre ^a   Vernant, Jean Paul ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOTYPE; ARTICLE; CELL POPULATION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RELAPSE; RISK FACTOR;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; STEM CELLS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSPLANTATION CONDITIONING;

EID: 0030726791     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710270-00012     Document Type: Article

References (50)

1. Ramsey N, Kersey JH, Robinson L, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392.
2. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729.
3. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667.
4. Bortin MM. Acute graft-versus-host disease following bone marrow transplantation in humans: prognostic factors. Transplant Proc 1987; 19: 2655.
5. Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA identical bone marrow. Blood 1984; 63: 1265.
6. Goulmy E: Minor histocompatibility antigens in man and their role in transplantation. Transplant Rev. 1988; 2: 29.
7. Perreault C, Decary F, Brochu S, Gyger M, Belanger R, Roy D. Minor histocompatibility antigens. Blood 1990; 76: 1269.
8. Filipovich AH, McGlave P, Ramsay NK, Goldstein G, Warkentin P, Kersey JH. Pretreatment of donor bone marrow transplantation with monoclonal OKT3 for prevention of acute graft- versus-host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1982; 1: 1266.
9. Champlin RE, Ho WG, Mitsuyasu R, et al. Graft failure and leukemia relapse following T lymphocyte depleted bone marrow transplants: effects of intensification of immusuppressive conditioning. Transplant Proc 1987; 19: 2616.
10. Maraninchi D, Gluckman E, Biaise D, et al. Impact of T cell depletion on outcome of allogeneic bone marrow transplant for standard risk leukemias. Lancet 1987; 2: 175.
11. Butturini A, Gale RP. T-cell depletion in bone marrow transplant for leukemia: current results and future directions. Bone Marrow Transplant 1988; 3: 185.
12. Marmont AM, Gale RP, Butturini A, et al. T-cell depletion in allogeneic bone marrow transplantation: progress and problems. Haematologica 1989; 74: 235.
13. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity and tolerance after bone marrow transplantation. Blood 1991; 77: 2515.
14. DeGast GC, Mickelson EM, Beatty PG, et al. Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia. Bone Marrow Transplant 1992; 9: 87.
15. Vogelsang GB, Hess A, Berkman AW. An in vitro predictive test for graft-versus-host disease in patients with genotypic HLA identical bone marrow transplants. N Engl J Med 1985; 313: 645.
16. Bagot M, Cordonnier C, Tilkin F, et al. A possible predictive test for graft-versus-host disease in bone marrow graft recipients: the mixed epidermal cell-lymphocyte reaction. Transplantation 1986; 41: 316.
17. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host- specific interleukin-2 secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613.
18. Schwarer AP, Jiang YZ, Brookes PA, et al. Frequency of anti- recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Lancet 1993; 341: 203.
19. Barnes DWH, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J 1956; 2: 626.
20. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529.
21. Aizawa S, Sado T. Graft-versus-leukemia effect in MHC compatible and incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991; 52: 885.
22. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.
23. Champlin R. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation. Semin Hematol. 1992; 29 (suppl 2): 46.
24. Van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181.
25. Storb R, Deeg HJ, Pepe MS, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long term follow-up of a controlled trial. Blood 1989; 73: 1729.
26. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295.
27. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225.
28. Orosz CG, Adams P, Ferguson R. Frequency of human allo antigen reactive T lymphocytes: method for limiting dilution analysis of allo antigen reactive helper T cells in human peripheral blood. Transplantation 1987; 43: 718.
29. Orosz CG, Bishop DK. Limiting dilution analysis of alloreactive T cells status and distribution during allograft rejection. Hum Immunol 1990; 28: 72.
30. Bishop DK, Orosz CG. Limiting dilution analysis for alloreactive TCGH secretory T cells. Transplantation 1989; 47: 671.
31. Deacock S, Schawer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2 producing cells in human. J Immunol Methods 1992; 147: 83.
32. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126: 1614.
33. Bonnefoix T, Sotto JJ. A program for computing the results of limiting dilution experiments. J Immunol Methods 1991; 144: 145.
34. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838.
35. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81: 249.
36. Aschan J. Treatment of moderate to severe acute graft-versus- host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601.
37. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate to severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk and outcome. Blood 1990; 75: 1024.
38. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966; 62: 21.
39. Vogelsang GB, Hess D. Graft-versus-host disease: new direction for a persistent problem. Blood 1994; 84: 2061.
40. Antin HJ, Ferrara JLM. Cytokine dysregulation and acute graft- versus-host disease. Blood 1992; 80: 2964.
41. Delmonte L, O'Reilly RJ, Kirkpatrick D, Kapoor N. In vitro model for detection of alloreactivity between HLA-matched donor-host pairs: preliminary evaluation as a predictor of graft-versus-host disease. Transplantation 1982; 34: 100.
42. Johnsen HE, Mickelson EM, Beatty PG, Hansen JA. Donor alloreactivity may predict acute graft-versus-host disease in patients receiving marrow transplants from HLA identical siblings. Bone Marrow Transplant 1992; 9: 91.
43. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397.
44. Biaise D, Guyotat D, Reiffers J, et al. Prospective randomized study of GVHD prevention using anti IL-2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT). Bone Marrow Transplant 1991; 7 (suppl 1): 150.
45. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner D, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow graft. N Engl J Med 1979; 300: 1068.
46. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981; 13: 248.
47. Slavin S, Ackerstein E, Naparstek E, Or R, Weiss L. Hypothesis. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bone Marrow Transplant 1990; 6: 155.
48. Brenner MK, Heslop HE. Graft versus leukemia effects after marrow transplantation in man. Bailliere's Clin Haematol 1991; 4: 727.
49. van Lochem E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181.
50. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82: 2273.